Matches in SemOpenAlex for { <https://semopenalex.org/work/W937758612> ?p ?o ?g. }
- W937758612 endingPage "224" @default.
- W937758612 startingPage "203" @default.
- W937758612 abstract "Breast cancer is a heterogeneous disease sustained by the dysregulation of numerous molecular pathways, such as cell cycle progression, angiogenesis, and apoptosis. Recent progress in molecular technology has allowed better characterization of the transformed phenotype, identifying molecular features that distinguish tumor from normal tissue and represent rational targets for more selective therapeutic approaches. In this chapter, we focus on the molecular target-based agents in the most advanced state of clinical development in breast cancer. Trastuzumab, a monoclonal antibody with high specificity for the HER2 protein, is the first targeted agent approved for the treatment of metastatic and early breast cancer. Bevacizumab, a monoclonal antibody directed against the VEGF-A ligand, with antiangiogenetic properties, and lapatinib, a dual tyrosine-kinase inhibitor of both EGFR and HER2, have been recently approved for use in the treatment of metastatic breast cancer. Several other compounds directed against different targets have also entered clinical evaluation. Key issues in the clinical development of targeted therapy include the proper selection of patients, the identification of the optimal combinations with conventional treatments, predictive markers of activity and toxicity, and the most appropriate therapeutic strategies." @default.
- W937758612 created "2016-06-24" @default.
- W937758612 creator A5003735951 @default.
- W937758612 creator A5009473646 @default.
- W937758612 creator A5015740152 @default.
- W937758612 creator A5051933262 @default.
- W937758612 creator A5062149201 @default.
- W937758612 creator A5078566173 @default.
- W937758612 creator A5079213613 @default.
- W937758612 creator A5073774460 @default.
- W937758612 date "2009-01-01" @default.
- W937758612 modified "2023-09-27" @default.
- W937758612 title "Integration of Target-Based Agents in Current Protocols of Breast Cancer Therapy" @default.
- W937758612 cites W1836239578 @default.
- W937758612 cites W1886850372 @default.
- W937758612 cites W1914269090 @default.
- W937758612 cites W1925485320 @default.
- W937758612 cites W1969328947 @default.
- W937758612 cites W1969875009 @default.
- W937758612 cites W1985804036 @default.
- W937758612 cites W1994001783 @default.
- W937758612 cites W1996920020 @default.
- W937758612 cites W2009402447 @default.
- W937758612 cites W2013125998 @default.
- W937758612 cites W2017018900 @default.
- W937758612 cites W2020499692 @default.
- W937758612 cites W2022233074 @default.
- W937758612 cites W2028647675 @default.
- W937758612 cites W2029620489 @default.
- W937758612 cites W2030754505 @default.
- W937758612 cites W2035332337 @default.
- W937758612 cites W2035484878 @default.
- W937758612 cites W2044833729 @default.
- W937758612 cites W2048686497 @default.
- W937758612 cites W2059890247 @default.
- W937758612 cites W2064047613 @default.
- W937758612 cites W2068014745 @default.
- W937758612 cites W2075880681 @default.
- W937758612 cites W2085772474 @default.
- W937758612 cites W2086224272 @default.
- W937758612 cites W2092491717 @default.
- W937758612 cites W2096074600 @default.
- W937758612 cites W2096499163 @default.
- W937758612 cites W2100506877 @default.
- W937758612 cites W2101565400 @default.
- W937758612 cites W2103019840 @default.
- W937758612 cites W2104126300 @default.
- W937758612 cites W2105196235 @default.
- W937758612 cites W2110444464 @default.
- W937758612 cites W2112001957 @default.
- W937758612 cites W2112720107 @default.
- W937758612 cites W2113361623 @default.
- W937758612 cites W2113670583 @default.
- W937758612 cites W2114159573 @default.
- W937758612 cites W2114974083 @default.
- W937758612 cites W2115759102 @default.
- W937758612 cites W2117188579 @default.
- W937758612 cites W2120220319 @default.
- W937758612 cites W2121500370 @default.
- W937758612 cites W2126150817 @default.
- W937758612 cites W2126275851 @default.
- W937758612 cites W2126620646 @default.
- W937758612 cites W2136704455 @default.
- W937758612 cites W2139135964 @default.
- W937758612 cites W2140684853 @default.
- W937758612 cites W2141393790 @default.
- W937758612 cites W2142506125 @default.
- W937758612 cites W2142752401 @default.
- W937758612 cites W2143673928 @default.
- W937758612 cites W2144124503 @default.
- W937758612 cites W2145224595 @default.
- W937758612 cites W2146384083 @default.
- W937758612 cites W2146406055 @default.
- W937758612 cites W2146681242 @default.
- W937758612 cites W2146778486 @default.
- W937758612 cites W2147094816 @default.
- W937758612 cites W2147394591 @default.
- W937758612 cites W2148860061 @default.
- W937758612 cites W2149218373 @default.
- W937758612 cites W2149773268 @default.
- W937758612 cites W2149908785 @default.
- W937758612 cites W2149997750 @default.
- W937758612 cites W2153242757 @default.
- W937758612 cites W2154027407 @default.
- W937758612 cites W2158158704 @default.
- W937758612 cites W2159305151 @default.
- W937758612 cites W2159459001 @default.
- W937758612 cites W2165824128 @default.
- W937758612 cites W2167766783 @default.
- W937758612 cites W2232313749 @default.
- W937758612 cites W2243880667 @default.
- W937758612 cites W2318605753 @default.
- W937758612 cites W2324278934 @default.
- W937758612 cites W2420889995 @default.
- W937758612 cites W2467250903 @default.
- W937758612 cites W4293395719 @default.
- W937758612 doi "https://doi.org/10.1007/978-1-60327-945-1_12" @default.
- W937758612 hasPublicationYear "2009" @default.